文献速递神经MR

钆增强T2 FLAIR是脑转移瘤患者放射性坏死与肿瘤进展的影像生物标志物

Gadolinium-Enhanced T2 FLAIR Is an Imaging Biomarker of Radiation Necrosis and Tumor Progression in Patients with Brain Metastases.
PubMed 文献 · AJNR Am J Neuroradiol · 2025-01-08

本单机构回顾性研究纳入56例接受治疗的脑转移瘤患者,评估钆增强T2 FLAIR(T2FLAIRc)鉴别放射性坏死(RN)与肿瘤进展(TP)的价值。RN组T2FLAIRc和T1c的z评分均显著高于TP组,T2FLAIRc的AUC(0.83)大于T1c(0.70),与DSC-derived相对CBV的AUC(0.82)无显著差异。结果表明T2FLAIRc有潜力作为RN的影像生物标志物。

要点

  • RN组T2FLAIRc z评分显著高于TP组(8.3 vs 5.8,P < .001)。
  • T2FLAIRc的AUC(0.83)大于T1c(0.70),差异有统计学意义(P = .04)。
  • T2FLAIRc与DSC-derived相对CBV的AUC(0.82)无显著差异(P = .9)。

核心结论

  • 放射性坏死组的标准化T1c和T2FLAIRc信号强度均高于肿瘤进展组;在单变量检验中,强化区平均T2FLAIRc信号强度对鉴别RN与TP显示出良好的判别性能,提示T2FLAIRc有潜力作为脑转移瘤患者RN评估中的影像生物标志物。

研究设计与样本

  • 单机构回顾性研究,纳入2021年1月至2023年6月间接受DSC-MRI的治疗后脑转移瘤患者56例(平均年龄62岁,SD 12.7;39例女性;RN 28例,TP 28例);参考标准基于组织病理学或连续随访(包括首次DSC-MRI后至少6个月的DSC-MRI结果);指标检查作为本机构脑肿瘤MRI方案的一部分,在首次DSC-MRI之前进行。

关键影像表现/征象

  • T2FLAIRc和钆增强T1(T1c)MPRAGE信号均以正常脑实质为参照进行标准化,并以z评分表示。
  • RN组T2FLAIRc z评分显著高于TP组(8.3 vs 5.8,P < .001)。
  • RN组T1c z评分显著高于TP组(4.1 vs 3.5,P = .02)。

诊断标准与关键数值

  • T2FLAIRc鉴别RN与TP的AUC为0.83(95% CI,0.72-0.92)。
  • T1c鉴别RN与TP的AUC为0.70(95% CI,0.56-0.83)。
  • T2FLAIRc的AUC大于T1c,差异有统计学意义(P = .04)。
  • DSC-derived相对CBV的AUC为0.82(95% CI,0.70-0.93),与T2FLAIRc的AUC无显著差异(P = .9)。

临床应用与阅片要点

  • 指标MRI平均在首次DSC-MRI前73天(SD 34)完成,T2FLAIRc作为本机构脑肿瘤MRI方案的组成部分实施。
  • 作者认为T2FLAIRc有潜力作为脑转移瘤患者放射性坏死评估中的影像生物标志物。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND AND PURPOSE: Differentiating radiation necrosis (RN) from tumor progression (TP) after radiation therapy for brain metastases is an important clinical problem requiring advanced imaging techniques that may not be widely available and are challenging to perform at multiple time points. The ability to leverage conventional MRI for this problem could have a meaningful clinical impact. The purpose of this study was to explore contrast-enhanced T2 FLAIR (T2FLAIRc) as a new imaging biomarker of RN and TP.

MATERIALS AND METHODS: This single-institution retrospective study included patients with treated brain metastases undergoing DSC-MRI between January 2021 and June 2023. Reference standard assessment was based on histopathology or serial follow-up, including the results of DSC-MRI for a minimum of 6 months from the first DSC-MRI. The index test was implemented as part of the institutional brain tumor MRI protocol and preceded the first DSC-MRI. T2FLAIRc and gadolinium-enhanced T1 (T1c) MPRAGE signal were normalized against normal brain parenchyma and expressed as a z score. The mean signal intensity of enhancing disease for the RN and TP groups was compared using an unpaired t test. Receiver operating characteristic curves and area under the receiver operating characteristic curve (AUC) were derived by bootstrapping. The DeLong test was used to compare AUCs.

RESULTS: Fifty-six participants (mean age, 62 [SD, 12.7] years; 39 women; 28 with RN, 28 with TP) were evaluated. The index MRI was performed, on average, 73 [SD, 34] days before the first DSC-MRI. Significantly higher z scores were found for RN using T2FLAIRc (8.3 versus 5.8, P < .001) and T1c (4.1 versus 3.5, P = .02). The AUC for T2FLAIRc (0.83; 95% CI, 0.72-0.92) was greater than that for T1c (0.70; 95% CI, 0.56-0.83) (P = .04). The AUC of DSC-derived relative CBV (0.82; 95% CI, 0.70-0.93) was not significantly different from that of T2FLAIRc (P = .9).

CONCLUSIONS: A higher normalized T1c and T2FLAIRc signal intensity was found for RN. In a univariable test, the mean T2FLAIRc signal intensity of enhancing voxels showed good discrimination performance for distinguishing RN from TP. The results of this work demonstrate the potential of T2FLAIRc as an imaging biomarker in the work-up of RN in patients with brain metastases.

来源:AJNR Am J Neuroradiol,查看原文。版权归原作者所有。

引用

  1. Heyn C, Bishop J, Moody AR, et al. Gadolinium-Enhanced T2 FLAIR Is an Imaging Biomarker of Radiation Necrosis and Tumor Progression in Patients with Brain Metastases. AJNR Am J Neuroradiol. 2025. PMID: 39107039. doi:10.3174/ajnr.A8431

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。